Uncategorized

CMS’s finalized national coverage determination (NCD) last night should support an incremental ~120 bps in growth for EW’s TAVR franchise in 2027, with the agency largely codifying the criteria initially outlined in its June proposal….

We believe control of the Senate is a toss-up, although, if forced to choose, we give Republicans a slight edge in retaining control of the upper chamber. We continue to think Democrats are very likely…

With the November elections less than two months away, we assess how different congressional outcomes could reshape the healthcare legislative agenda for health insurers, pharmacy benefit managers (PBMs), 340B contract pharmacies, and health savings account…

With CMS set to release its finalized update to the TAVR NCD by Sept. 13 [likely posted after the close here], we largely expect it to maintain the core elements of the original proposal. More…

Our review of stakeholder feedback on CMS’s CY27 Medicare payment rule for dialysis centers [DVA, FRE.DE, private US Renal Care and Innovative Renal Care] leaves us expecting a final rule similar to the June proposal,…

The House is in session this week but will be out next week for the Labor Day district work period. The Senate will not return until the week of September 14. In addition to looking…

Following reports that the Trump administration is considering eliminating the tariff exemptions for data centers and extending Sec. 232 semiconductor tariffs to servers and other chip products, we assign ~70% odds that Trump announces expanded…

Bloomberg is reporting that the White House intends to “announce a new round of drug pricing agreements with several midsized biotech companies on Monday,” and that “in exchange, the companies will be exempt” from the…

We think Meta’s (META) settlement with state attorneys general (AG) is positive for the company and the social media industry. The state AG cases were the largest and most advanced litigation threat facing the company,…

This fall seems likely to be a busy one for medtech and biopharma, with key policy catalysts coming up for a number of companies. These span from both the far-reaching in terms of most favored…